Transesophageal echocardiography and lung cancer staging

Cardiac involvement by tumour is found in 25% of patients who die from lung cancer and, in the majority of these patients, the involvement is asymptomatic. With a significant proportion of patients subjected to lung cancer surgery dying from disease progression within 6 months of surgery, the British Thoracic Society guidelines on the selection of patients with lung cancer for surgery may help to reduce this number. These guidelines acknowledge the excellent staging potential of PET scanning but only mention echocardiography in the context of valvular or ischaemic heart disease. Echocardiography is an excellent modality for detecting cardiac malignancy. An increasing number of anaesthetists are joining the already large number of cardiologists able to perform transoesophageal echocardiography (TOE). We suggest that patients presenting for lung cancer surgery who have either ECG abnormalities or poorly differentiated paracardiac tumours should undergo TOE before thoracotomy. The TOE examination would add little to the total operative time but would add contemporary information to existing older information regarding disease stage. Moreover, there would be a small number of patients who would be spared thoracotomy.

A recent case in which left atrial extension of a lung cancer was demonstrated by intraoperative TOE but missed by preoperative PET scanning and the standard staging methods lends anecdotal weight to our argument. Not only did our patient suffer an unnecessary thoracotomy, but also left popliteal artery tumour embolism. This is not the first time a patient has had a thoracotomy abandoned because of tumour involvement of the left atrium revealed only by intraoperative TOE. In both cases TOE in the anaesthetic room would have prevented thoracotomy and, in our case, distant tumour embolisation may not have occurred.

J M Maskill
Barnsley District General Hospital, Barnsley, UK; jmaskill@aol.com
A Rother, S Seevanayagam
Monash Medical Centre, Melbourne, Australia

Reference

Asthma guidelines

We read with interest the new British guideline on the management of asthma published recently as a supplement to Thorax. The evidence review groups and guideline authors are to be congratulated on the production of a document of exceptional clarity and ease of use. There is no doubt that adherence to the guideline could contribute substantially to the better management of asthma in the majority of adults, including most elderly patients. However, we feel moved to point out the lack of reference to the difficulties of diagnosis and treatment in patients with abnormalities of cognition, praxis, dexterity and executive function, most of whom are elderly with varying degrees of dementia and/or cerebrovascular disease. This is a retrograde step as earlier versions of the asthma guideline referred to some of these issues. We see this as a missed opportunity to improve the detection and management of asthma in this group of patients who are known to have a high level of morbidity from that condition (class 2 evidence), and in whom the asthma mortality curve is not falling (class 1 evidence). Some of the most recent published work in this domain will not have been included in the evidence trawl for the guideline. Nevertheless, there is ample evidence in the literature relating to the quality of clinical information (class 2+ and 3) in such patients, including spirometry (class 2+) and on the issues of inhaler device competence (class 2+ and 3) and selection and training (class 2+). There is also class 2+ evidence that elderly subjects are less able than younger subjects to detect changes in airflow resistance, which has implications for reliever therapy at steps 1 and 2 of the guideline. We strongly advocate that future revisions of the guideline should take account of this evidence, probably as a grade C recommendation or good practice point.

S Allen
The Royal Bournemouth Hospital, Bournemouth, UK

M Connolly
Manchester Royal Infirmary, Manchester, UK

C Dyer
The Royal United Hospital, Bath, UK

M Gosney
The Royal Liverpool Hospital, Liverpool, UK

Correspondence to: Dr S C Allen, The Royal Bournemouth Hospital, Bournemouth, Dorset BH7 7DW, UK; stephen.allen@rbch-tr.swest.nhs.uk

Authors’ reply

We thank Dr Allen and colleagues for raising these issues. As they point out, the difficulties of diagnosis and treatment are mainly features of the co-morbidity which increases with age, not age itself, and we had not felt it desirable or possible to cover all the changes to routine practice which might be required because of the presence of other diseases. We cannot comment on the items of evidence included in their letter since references are not given, except to say that their points seem correct in principle but some of the evidence levels look unrealistic—for example, one of the flaws of the current grading system is that, however good the evidence on something like asthma mortality, it cannot be level 1 evidence since that is possible for randomised controlled trials only. Nonetheless, we agree that general reference to the potential problems in this patient group might be appropriate and we will consider this in the next version of the guideline.

B G Higgins
Freeman Hospital, Newcastle upon Tyne, UK

G Douglas
Aberdeen Royal Infirmary, Aberdeen, UK

Correspondence to: Dr B G Higgins, Freeman Hospital, Newcastle upon Tyne NE7 7WD, UK; b.g.higgins@ncl.ac.uk

Self-management of asthma in general practice

We welcome the paper by Thomoon and colleagues on self-management of asthma in general practice1 as we firmly believe that self-management of chronic diseases is a promising area for innovation in general practice. We wondered whether differential withdrawals—specifically, the difference between groups in the number of patients for whom successfully treated weeks could be calculated—may have affected the outcomes. As reported, 92% of the patients in the usual care (UC) group provided data for this primary outcome compared with 85% of the self-management (SM) group. The mean percentage of successfully treated weeks was 72%
and 78% for the UC and SM groups, respectively, a difference reported to be statistically significant. As we do not expect that these specific outcomes were analysed on an intention to treat basis, non-random withdrawal might have biased the findings—for example, when most patients who withdrew from the SM group did so because they were not able to comply with the SM programme and their asthma was badly controlled, this would affect the outcomes, inflating the differences in favour of the SM group.

J C van der Wouden, R D W van Bentvelzen, B Fu, K S ter Meulen, P A Muller
Department of General Practice, Erasmus MC University Medical Center Rotterdam, P O Box 1738, 3000 DR Rotterdam, The Netherlands; j.vanderwouden@erasmusmc.nl

Reference

Authors’ reply
In their letter van der Wouden and colleagues question the issue of selective withdrawal of subjects from the two study groups which may have had consequences for the validity of our conclusions. As a possible source of bias in calculating successfully treated weeks this may be an important issue which was not discussed in depth in our original paper.

To address this question we performed an additional analysis of the study records of all subjects included in the two study groups which may have had consequences for the validity of our conclusions. As a possible source of bias in calculating successfully treated weeks this may be an important issue which was not discussed in depth in our original paper.

To address this question we performed an additional analysis of the study records of all subjects included in the two study groups which may have had consequences for the validity of our conclusions. As a possible source of bias in calculating successfully treated weeks this may be an important issue which was not discussed in depth in our original paper.

To address this question we performed an additional analysis of the study records of all subjects included in the two study groups which may have had consequences for the validity of our conclusions. As a possible source of bias in calculating successfully treated weeks this may be an important issue which was not discussed in depth in our original paper.

Bronchoscopy in patients with suspected PCP: supine or sitting?

We read with interest the case report by Newton et al describing platypnoea and orthodeoxia in a patient with pneumocystis pneumonitis (PCP). We do not like to add our own experience and question whether the observation has an important clinical implication. A 29 year old patient who had been born and raised in Zambia presented 10 months after arrival in the UK with a history of cough and progressive dyspnoea. A chest radiograph showed bilateral diffuse lung shadowing, maximal in the perihilar regions and lower zones, but with relative sparing of the lung bases. Fae, bronchoscopic examination of BAL performed. Sedation was with 2 mg midazolam. The bronchoscopy, which was performed with the patient sitting, was complicated by a fall in SaO2 to 85% which was only partially corrected by supplemental oxygen. Pneumocystis was identified in the BAL fluid sample and treatment commenced with high dose co-trimoxazole. The day after the bronchoscopic examination, while supine and breathing air, the patient had an SaO2 of 98%. Rising to the sitting position led to a steady fall in SaO2 to 94%, which rapidly corrected to 99% when the patient returned to the supine position.

Our patient showed orthodeoxia similar to that described by Newton et al. This became clinically important when bronchoscopy was performed in the sitting position. Predominantly mid and lower zone shadowing is a common radiographic feature in PCP and we wonder whether the phenomenon of platypnoea and orthodeoxia may be widespread in such patients. A study to identify the frequency of this finding would be worthwhile and easy to do. We suggest that supine and sitting SaO2 measurement should be routine before bronchoscopic investigation in such patients and that bronchoscopy in the supine position might be the approach of choice for patients with suspected PCP.

P Vijayanand, M Woodhead
Department of Respiratory Medicine, Manchester Royal Infirmary, Manchester M13 9WL, UK; mark.woodhead@mmcr.nhs.uk

References

Atopic cough: little evidence to support a new clinical entity

A cough is by far the most common reason for a patient to seek medical advice.1 Most of these consultations are for acute cough caused by a myriad of respiratory viruses. In practice, we do not attempt to differentiate rhinovirus infection from adenovirus because no important consequence arises from this diagnostic precision. In chronic cough numerous studies have shown that the overwhelming majority of patients are suffering from one of three conditions: a form of asthma, gastro-oesophageal reflux, or rhinitis.2 The question is whether any further subdivision is justified or merely muddies the water.

In their recent paper published in Thorax Fujimura and colleagues, by inventing a diagnosis of “atopic cough”, have succeeded in adding further unnecessary complexity to the area.3 There are many aspects of this paper which cannot be left unchallenged and we have outlined these below.

The evidence to support a new clinical entity of “atopic cough” is tenuous and is further hampered by the extremely vague term “probable atopic cough”. This point is well illustrated in their table 2 which outlines a variety of diagnostic permutations possible after interpretation of a selection of clinical findings. We suspect the authors have, in a significant number of these “probable” patients, merely described atopic individuals with cough predominant asthma. Certainly the demonstration of bronchial hyperreactivity (BHR) in 15 such patients (median PC20, 2.5 mg/ml, range 1.25–5.0), many of whom had airway eosinophilia and all of whom appear atopic, is suggestive. Such diagnostic imprecision may yet have therapeutic consequences, but the authors do not provide sufficient information in the paper to conclude that these patients failed to respond to steroids, and have indicated that response to bronchodilators was tested in neither a randomised nor a controlled way.

The authors have relied heavily on the “absence of transformation to typical asthma” to differentiate atopic cough from asthmatic cough. Such a conclusion can hardly be supported by a telephone follow up which relies on patient recall and subjective assessment of symptoms. In some series up to one third of patients with cough predominant asthma may develop typical asthma symptoms,4 although in a 3 year follow up of 63 patients with cough variant asthma typical wheeze occurring in only 6%.5 Thus, lack of progression to typical asthma in the asthmatic cough described and cannot be used to support the proposition that atopic cough is unique.

The statement “the defining physiological feature is increased cough sensitivity without BHR in atopic cough, and BHR in nonatopic cough hypersensitivity in cough variant asthma” is simply untrue. Capsaicin hypersensitivity in patients with asthmatic cough has been reported by many researchers.6 Cough is a phenomenon of the respiratory tract and n of cough variant asthma is simply not related to bronchomotor tone, but most probably reflects a different pattern of airway inflammation.7

With reference to the authors’ interpretation of the study by McGarvey et al,8 we strongly contest the suggestion that patients identified as having cough variant asthma may have been misclassified. In this study steroid efficacy was not a sole criterion for the diagnosis of cough variant asthma as all 10 patients had BHR (mean PC20, 3.44 mg/ml, range 0.04–8). Only two of these patients were atopic.

We believe our clinical understanding of asthmatic cough is enhanced by the recognition that an individual patient may show different features of the disease process. The unnecessary subdivision into arbitrarily defined “diseases” such as atopic cough (or, indeed, eosinophilic bronchitis) is not helpful either diagnostically or therapeutically.

L McGarvey
Department of Medicine, Institute of Clinical Science, The Queen’s University of Belfast, Belfast BT12 6BJ, UK; lmcgarvey@qub.ac.uk

A H Morice
Academic Department of Medicine, School of Medicine, Castle Hill Hospital, Cottingham HU16 5QG, UK
independent.

or bronchial responsiveness are entirely and cough sensitivity and bronchomotor tone tations of eosinophilic airway inflammation, medical science. It is very important to recog- insistence runs counter to the progress of well as in asthma and cough variant asthma, aetiological entity in 1992, a number of Japa-

Since we proposed atopic cough as an diagnosis of atopic cough did not go on to treatment.

tify again that bronchodilators, which asthmatic eosinophilic airway disorders. We

emphasise that bronchodilators, which are effica-


References


M Fujimura
Division of Respiratory Medicine, Cellular Transplantation Biology, Kanazawa Graduate University School of Medicine, Kanazawa
920-8641, Japan; fujimura@med3.m.kanazawa-u.ac.jp

H Ogawa
Division of Pulmonary Medicine, Saiseikai Kanazawa Hospital, Kanazawa
920-0353, Japan

www.thoraxjnl.com

Figure 1 Recognition of cough variant asthma, atopic cough, and eosinophilic bronchitis without asthma based on bronchial responsiveness and bronchodilator response in chronic coughers with eosinophilic airway inflammation.

Figure 1 shows a consensus opinion of the Japanese Cough Research Society concerning the diagnosis of cough variant asthma and atopic cough based on bronchial responsiveness and efficacy of bronchodilators. Furthermore, it has been clearly shown that measurement of bronchial responsiveness cannot predict the efficacy of bronchodilators in the treatment of cough. 1

years after her first visit. Although the patient’s bronchial responsiveness was increased, her bronchial reversibility and diurnal variation in peak expiratory flow rate were within normal limits; broncho-
dilator treatment was not effective, leading to a probable diagnosis of atopic asthma. Although some investigators believe that the BHR is the key criterion for a diagnosis of cough variant asthma, this is incorrect. The most important feature of cough variant asthma is isolated chronic cough responsive to bronchodilators. 2

Additionally, we will continue to suggest that such insistence runs counter to the progress of medical science. It is very important to recogn-

ise that there are different clinical manifestations of eosinophilic airway inflammation, and cough sensitivity and bronchomotor tone or bronchial responsiveness are entirely independent. 3 4 Two mechanisms of non-

productive cough are generally recognised: cough triggered by increased bronchomotor tone and cough based on increased cough sensitivity. Both may result from eosinophilic airway inflammation, although via different mechanisms. We do not yet fully understand why eosinophilic airway inflammation increases cough sensitivity in atopic cough while both asthma and cough variant asthma exhibit mild bronchial hyperresponsiveness (BHR) without increased cough sensitivity. We believe that future studies will disclose the mechanism, thereby contributing to both our understanding of the pathophysiology of atopic cough and to better specific treatment.

In our study 5 patients with a definite diagnosis of atopic cough did not go on to develop typical asthma, indicating that atopic cough is not a precursor to asthma. Only one of 58 patients with a probable diagnosis of atopic cough developed typical asthma. 11-3

patients in a randomised and placebo controlled manner, the assessment we used is not difficult. 6 Although the placebo effect may lead to an incorrect diagnosis of cough variant asthma, no effect is meaningful enough to exclude cough variant asthma or cough predominant asthma.

One fundamental feature of cough variant asthma is mildly increased bronchial responsiveness unrelated to cough sensitivity. It is well known that cough sensitivity is increased in some patients with cough variant asthma and asthma (asthmatic patients), as pointed out by McGarvey and Morice. Our opinion is that increased cough sensitivity is a complication in asthmatic patients but it is not a fundamental aspect of the asthmatic airway. We label such patients as having “cough variant asthma” or “asthma complicated with cough hypersensitivity”. In these patients bronchodilator therapy is not sufficient; histamine H1-antagonists are useful, as shown by Shioya et al. 7 Corticosteroids do, of course, relieve the cough because they improve both cough hypersensitivity and BHR which are caused by eosinophilic airway inflammation via possibly different mecha-

The data presented in our paper 8 showing that six of 20 patients with cough variant asthma not taking long term inhaled cortico-

steroid therapy developed typical asthma are consistent with previous reports. Although Orejas et al. 9 reported that typical asthma occurred in only 6% of 63 patients with cough variant asthma during a 3 year follow up period, there exists an important problem in the diagnostic criteria for cough variant asthma. Orejas et al. and many other investiga-

 tors have diagnosed cough variant asthma based on BHR without assessing the efficacy of bronchodilator therapy or measuring cough sensitivity, resulting in the inclusion of non-asthmatic patients who, in fact, have atopic cough. McGarvey and Morice and other investiga-

tors feel that subdividing eosinophilic airway disorder causes unwieldy complexity in the diagnosis of chronic cough. We hold that delineating the pathophysiology of specific subdivisions such as atopic cough and cough variant asthma will allow more effective and specific treatments to be used rather than relying solely on inhaled corticosteroids which are non-specific to the actual cough mechanism. We continue to suggest that atopic cough should be considered as an entity separate from cough variant asthma, with a unique pathophysiology and its own rate of asthma onset.

H Ogawa
Division of Pulmonary Medicine, Ishikawaken Saiseikai Kanazawa Hospital, Kanazawa
920-0353, Japan

www.thoraxjnl.com

Downloaded from http://thorax.bmj.com/ on June 22, 2017 - Published by group.bmj.com

References

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are health care professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Currently, we are interested in finding contributors with an interest in the following clinical areas:
- Altitude sickness
- Autism
- Basal cell carcinoma
- Breast feeding
- Carbon monoxide poisoning
- Cervical cancer
- Cystic fibrosis
- Endometriosis
- Hodgkin's disease
- Infectious mononucleosis (glandular fever)
- Kidney stones
- Malignant melanoma (metastatic)
- Mesothelioma
- Myeloma
- Ovarian cyst
- Pancreatitis (acute)
- Pancreatitis (chronic)
- Polymyalgia rheumatica
- Post-partum haemorrhage
- Pulmonary embolism
- Recurrent miscarriage
- Repetitive strain injury
- Scoliosis
- Seasonal affective disorder
- Squint
- Systemic lupus erythematosus
- Testicular cancer
- Varicocele
- Viral meningitis
- Vitiligo

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:
- Appraising the results of literature searches (performed by our Information Specialists) to identify high quality evidence for inclusion in the journal.
- Writing to a highly structured template (about 2000–3000 words), using evidence from selected studies, within 6–8 weeks of receiving the literature search results.
- Working with Clinical Evidence Editors to ensure that the text meets rigorous epidemiological and style standards.
- Updating the text every eight months to incorporate new evidence.
- Expanding the topic to include new questions once every 12–18 months.

If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Claire Folkes (cfolkes@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are health care professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and health care professionals, possibly with limited statistical knowledge). Topics are usually 2000–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicaledgevidence.com or contact Claire Folkes (cfolkes@bmjgroup.com).
Atopic cough: little evidence to support a new clinical entity

L McGarvey and A H Morice

Thorax 2003 58: 736-738
doi: 10.1136/thorax.58.8.736-a

Updated information and services can be found at: http://thorax.bmj.com/content/58/8/736.2

These include:

References
This article cites 16 articles, 5 of which you can access for free at: http://thorax.bmj.com/content/58/8/736.2#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/